Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 331.13B | 332.59B | 303.92B | 338.57B | 344.05B |
Gross Profit | 127.67B | 120.35B | 110.75B | 158.03B | 162.41B |
EBITDA | 29.06B | 32.54B | 27.93B | 35.09B | 34.36B |
Net Income | 8.11B | 14.13B | 8.10B | 13.52B | 11.84B |
Balance Sheet | |||||
Total Assets | 377.77B | 395.74B | 369.05B | 356.74B | 340.08B |
Cash, Cash Equivalents and Short-Term Investments | 60.24B | 97.20B | 91.93B | 102.25B | 98.64B |
Total Debt | 165.00M | 30.00B | 30.02B | 30.35B | 30.64B |
Total Liabilities | 105.18B | 132.63B | 124.30B | 115.57B | 117.53B |
Stockholders Equity | 272.00B | 262.54B | 244.29B | 240.79B | 221.75B |
Cash Flow | |||||
Free Cash Flow | -15.66B | 9.69B | -8.89B | 4.89B | 474.00M |
Operating Cash Flow | 1.81B | 28.06B | 16.80B | 28.65B | 17.22B |
Investing Cash Flow | -10.26B | -10.37B | -20.14B | -29.19B | -12.44B |
Financing Cash Flow | -39.15B | -6.09B | -10.28B | -4.86B | -9.74B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | ¥351.60B | 16.30 | 10.34% | 2.13% | 6.45% | 4.96% | |
72 Outperform | ¥263.74B | 21.55 | 6.83% | 3.47% | -15.46% | ||
68 Neutral | ¥198.41B | 21.33 | 8.29% | 2.33% | 4.99% | 3.05% | |
68 Neutral | €272.96B | 10.74 | 9.59% | 3.65% | 6.59% | 6.52% | |
63 Neutral | ¥300.35B | 52.42 | 2.66% | 2.58% | -90.84% | ||
61 Neutral | ¥255.15B | 16.20 | 1.99% | 25.63% | -24.35% | ||
54 Neutral | ¥304.76B | 54.89 | 2.04% | 1.92% | -3.24% | -63.77% |
Ezaki Glico Co., Ltd. announced the establishment of a special purpose company, Glico Europe B.V., in the Netherlands as part of its strategy to pursue global growth investments. This move aligns with the company’s mid-term management plan to expand its business into new areas and promote global growth, with a minor expected impact on the company’s earnings for the fiscal year ending December 31, 2025.